Who is sponsoring NCT03912870?

NCT03912870 is sponsored by Assistance Publique Hopitaux De Marseille.

What drugs are being tested in NCT03912870?

Interventions in NCT03912870: Value of Flow Cytometry in Infectious Point of Care.

What condition does NCT03912870 study?

NCT03912870 studies A Potential Infectious Respiratory Clinical Syndrome, Potential Clinical Urinary Infectious Syndrome, A Potential Clinical Abdominal Infection Syndrome.

Is NCT03912870 still recruiting?

NCT03912870 is currently completed. Last updated 12 May 2023.

Last reviewed 2023-05-12 · How we verify

NCT03912870

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Value of Flow Cytometry in Infectious Point of Care: Feasibility Study

Completed Last updated 12 May 2023

What this trial tests

trial testing Value of Flow Cytometry in Infectious Point of Care in A Potential Infectious Respiratory Clinical Syndrome in 96 participants. Completed in 11 May 2023.

Timeline

10 December 2018

Primary endpoint
5 June 2020

11 May 2023

Quick facts

Lead sponsor	Assistance Publique Hopitaux De Marseille
Status	Completed
Study type	OBSERVATIONAL
Enrollment	96
Start date	10 December 2018
Primary completion	5 June 2020
Estimated completion	11 May 2023
Sites	1 location across France

Drugs / interventions tested

Value of Flow Cytometry in Infectious Point of Care

Conditions studied

A Potential Infectious Respiratory Clinical Syndrome — all drugs for A Potential Infectious Respiratory Clinical Syndrome →
Potential Clinical Urinary Infectious Syndrome — all drugs for Potential Clinical Urinary Infectious Syndrome →
A Potential Clinical Abdominal Infection Syndrome — all drugs for A Potential Clinical Abdominal Infection Syndrome →

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

18 and older, any sex, with A Potential Infectious Respiratory Clinical Syndrome or Potential Clinical Urinary Infectious Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this project is to validate the diagnostic orientation properties of two new biomarkers (CD64, CD169) for patients with infectious syndromes arriving in emergency departments. This prospective observational study will focus on the quantification of these biomarkers on a hematology tube background (Pr Morange laboratory) without modifying the usual diagnostic and therapeutic procedures. The results of these assays will be compared with the diagnoses made at the end of treatment in order to determine their sensitivity and specificity. This study is the preliminary study, necessary to determine the detection characteristics of these biomarkers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

CD169 and CD64 could help differentiate bacterial from CoVID-19 or other viral infections in the Emergency Department.
Bourgoin P, Soliveres T, Barbaresi A, Loundou A, et al · · 2021 · cited 37× · PMID 33491921 · DOI 10.1002/cyto.a.24314

Verify or expand the search:

Other Assistance Publique Hopitaux De Marseille trials

Trials by the same sponsor.

NCT07521644 — Dysbiosis of Methanogenic Archaea and Nanoarchaea in the Oral Microbiome · NA · not yet recruiting
NCT07357025 — Resting-State fMRI Study of Functional Connectivity After Gamma Knife Radiosurgery in Trigeminal Neuralgia · NA · not yet recruiting
NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
NCT07399327 — Biomarkers of Response to SEEG Thermocoagulation · NA · not yet recruiting
NCT06999499 — Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03912870 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille
Last refreshed: 12 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03912870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing